Safety of crizotinib in 892 Japanese ALK-positive advanced NSCLC patients: Interim report of post-marketing surveillance

被引：0

作者：

Okamoto, Isamu ^{[1
]}

Nakagawa, Kazuhiko ^{[2
]}

Ohe, Yuichiro ^{[3
]}

Ueno, Naomi ^{[4
]}

Banno, Shigeo ^{[4
]}

Endo, Yutaka ^{[4
]}

Ohki, Emiko ^{[4
]}

Gemma, Akihiko ^{[5
]}

机构：

[1] Kyusyu Univ Hosp, Ctr Clin & Transrat Res, Fukuoka, Japan

[2] Kinki Univ, Fac Med, Dept Med Oncol, Osaka, Japan

[3] Natl Canc Ctr, Dept Resp Med, Tokyo, Japan

[4] Pfizer Japan Inc, Tokyo, Japan

[5] Nippon Med Sch, Grad Sch Med, Dept Pulm Med & Oncol, Tokyo 113, Japan

来源：

ANNALS OF ONCOLOGY | 2015年 / 26卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

SY12-3

引用

页码：37 / 37

页数：1

共 50 条

[21] Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC [J].

Ou, S. -H. I. ;

Jaenne, P. A. ;

Bartlett, C. H. ;

Tang, Y. ;

Kim, D. -W. ;

Otterson, G. A. ;

Crino, L. ;

Selaru, P. ;

Cohen, D. P. ;

Clark, J. W. ;

Riely, G. J. .

ANNALS OF ONCOLOGY, 2014, 25 (02) :415-422

[22] Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC [J].

Leduc, C. ;

Besse, B. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :2092-2092

[23] Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan [J].

Genma, Akihiko ;

Nakanishi, Yoichi ;

Nakagawa, Kazuhiko ;

Yamamoto, Nobuyuki ;

Saito, Takeshi ;

Tahara, Yasuhiro ;

Ohe, Yuichiro .

ANNALS OF ONCOLOGY, 2017, 28

[24] Safety Profile of Nivolumab in Japanese NSCLC Pts: Interim Results from Post-marketing All-Case Surveillance in Japan [J].

Genma, Akihiko ;

Nakanishi, Yoichi ;

Nakagawa, Kazuhiko ;

Yamamoto, Nobuyuki ;

Saito, Takeshi ;

Tahara, Yasuhiro ;

Ohe, Yuichiro .

ANNALS OF ONCOLOGY, 2017, 28 :75-75

[25] Efficacy of crizotinib in first-line treatment of adults with ALK-positive advanced NSCLC [J].

Zhang, Yi-chen ;

Zhou, Qing ;

Wu, Yi-Long .

EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (12) :1693-1701

[26] Crizotinib-Associated Toxic Epidermal Necrolysis in an ALK-Positive Advanced NSCLC Patient [J].

Yang, S. ;

Chen, X. ;

Ma, S. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) :S1950-S1950

[27] Crizotinib-associated toxic epidermal necrolysis in an ALK-positive advanced NSCLC patient [J].

Yang, Shaoyu ;

Wu, Liming ;

Li, Xin ;

Huang, Jie ;

Zhong, Jianbo ;

Chen, Xueqin .

MOLECULAR AND CLINICAL ONCOLOGY, 2018, 8 (03) :457-459

[28] Safety and Effectiveness of Natalizumab: First Report of Interim Results of Post-Marketing Surveillance in Japan [J].

Saida T. ;

Yokoyama K. ;

Sato R. ;

Makioka H. ;

Iizuka Y. ;

Hase M. ;

Ling Y. ;

Torii S. .

Neurology and Therapy, 2017, 6 (2) :197-211

[29] Safety and Efficacy of Fingolimod in Japanese Patients with Multiple Sclerosis: Interim Analysis Results from Post-marketing Surveillance [J].

Kira, J. ;

Fujihara, K. ;

Ueda, K. ;

Tajima, T. ;

Ueno, M. ;

Saida, T. .

MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) :928-928

[30] Impact of alectinib on survival after crizotinib failure in ALK-positive NSCLC patients [J].

Yoshida, T. ;

Oya, Y. ;

Tanaka, K. ;

Junichi, S. ;

Yoshitsugu, H. ;

Hida, T. ;

Yatabe, Y. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S619-S619

← 1 2 3 4 5 →